By Jeff Cranmer, Executive Editor
Mar 16, 2021 | 1:28 AM GMT
The solely factor that’s clear from the newest large Alzheimer’s readout is that the entrenched camps of amyloid believers and doubters will take predictably polarized views. On the newest BioCentury This Week podcast, BioCentury’s editors focus on the data for Lilly’s donanemab together with the newest considerations over AstraZeneca’s COVID-19 vaccine, the biologics-heavy focus of the continuing PDUFA negotiations, and what’s behind Takeda’s takeout of Maverick.
Editor in Chief Simone Fishburn sizes up the present controversy over the COVID vaccine from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) after a handful of main EU nations hit pause on their vaccination applications deploying the product. EMA says it’s watching the scenario, with a touch upon subsequent steps due late this week, whereas the U.Ok.’s MHRA and the corporate say they don’t see a sign.
“I don’t must let you know that the true hazard of that is vaccine skepticism — an increasing number of individuals are going to be involved about taking it,” Fishburn argues. “What many scientists are declaring is you could have a runaway pandemic, the hazard of dying and contracting COVID is much greater and outweighs the dangers.”